Skip to main content

08-07-2024 | Huntington's Disease | Editor's Choice | News

PROOF-HD: Pridopidine benefits HD patients not taking antidopaminergics

Author: Lucy Piper

medwireNews: The selective sigma-1 receptor agonist pridopidine improves function, motor, and cognitive outcomes in patients with Huntington’s disease (HD) who are not taking antidopaminergic medications, suggests an analysis of the PROOF-HD study.

Related topics